Other investigators have also analyzed the potential of hepcidin as a biomarker in other settings than in preoperative anemia treatment: Tables 4 and 5 show six studies that investigated the role of hepcidin as a potential biomarker for the response to iron treatment and/or a correlation between serum levels of hepcidin and ferritin [32–37]. The gene discussed is HAMP; the disease is anemia (phenotype).